Released Nov 9, 2023, after the close
10-Q filed Nov 9, 2023, 40 days after period end · 0001390478-23-000024
Q3 2023 · 10-Q
Revenue$0.00$0.00 — vs Q3 2022no prior Q2 2023 on file
Net Income-$9.27M-$9.27M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.33-$0.33 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$9,361,000N/M
Operating Cash Flowderived-$6,892,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$9.27M | -$7.02M | -$7.09M | -$4.47M |
| EPS Diluted | -$0.33 | -$0.34 | -$0.45 | -$0.53 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR